top of page
Life Saving Medicines
Remove the Cause, Remove the Effect
We are a biopharmaceutical company pioneering novel therapies for life-threatening and debilitating conditions caused by an excess of harmful substances in the body
Latest News from Clear Scientific
Clear Scientific team participates in The Dimock’s Center Annual Road to Wellness Run/Walk
Roxbury MA | Sept 2026 Last Saturday, the Clear Scientific team joined over 1,200 runners and walkers at The Dimock’s Center 11th Annual Road To Wellness Run/Walk at their Roxbury campus. Founded in 2015 through a partnership between HoodFit, the Boston Athletic Association, and The Dimock Center, the Road to Wellness has grown from what was once an idea into a year-round movement dedicated to health, fitness, and community empowerment. At the 11th Annual Road to Wellness: 1
Sep 15
NIH Highlights Pioneering Research by Drs. Cotten and Marota on using CS-1103 to Reverse Meth Poisoning by Protecting Against Overheating; Low Oxygen Levels; Organ Injury; and Muscle Breakdown
Cambridge, MA | August 2026 A novel drug sequestrant-based therapeutic candidate reverses methamphetamine-induced hyperthermia and hypermetabolism and abates multiorgan toxicity in rats - ScienceDirect In a preclinical study funded by the National Institute on Drug Abuse, CS-1103 protected against methamphetamine overdose, for which there are currently no medications. This pioneering work was conducted by Dr. Joe Cotten, MD, PhD and Dr. Elie Adam, PhD at Mass General Brigham
Sep 1
Clear Scientific Awarded $5.2M NIDA Grant for Meth Reversal Phase 2 Clinical Trial
Cambridge, MA | August 2026 Clear Scientific, a clinical-stage biopharmaceutical company, was awarded a $5.2M award from the NIH’s National Institute on Drug Abuse to continue the development of CS-1103 through Phase 2 clinical trials for the reversal of methamphetamine intoxication. Illicit stimulant use, especially methamphetamine, is a major public health crisis for which there are no FDA-approved therapeutics. Clear Scientific has raised an additional $2.6M in an open SA
Aug 18
bottom of page